Previous close | 2.2300 |
Open | 2.2300 |
Bid | 2.2800 x 1000 |
Ask | 2.3600 x 1000 |
Day's range | 2.2300 - 2.3500 |
52-week range | 1.9000 - 4.8300 |
Volume | |
Avg. volume | 41,252 |
Market cap | 105.441M |
Beta (5Y monthly) | 0.38 |
PE ratio (TTM) | N/A |
EPS (TTM) | N/A |
Earnings date | N/A |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | N/A |
CHESTER, N.Y., May 04, 2022--Repro Med Systems, Inc. dba KORU Medical Systems (NASDAQ: KRMD) ("KORU Medical" or the "Company"), a leading medical technology company focused on the development, manufacturing, and commercialization of innovative and easy-to-use specialty infusion solutions that improve quality of life for patients, today reported financial results for the first quarter ended March 31, 2022.
CHESTER, N.Y., May 02, 2022--Repro Med Systems, Inc. dba KORU Medical Systems (NASDAQ: KRMD) ("KORU Medical" or the "Company"), a leading medical technology company focused on the development, manufacturing, and commercialization of innovative and easy-to-use specialty infusion solutions that improve quality of life for patients, today announced 510k clearance for use of the KORU Medical FreedomEdge® infusion system to deliver pegcetacoplan 20 mL solution, branded as EMPAVELI® or Aspaveli® and c
CHESTER, N.Y., April 20, 2022--Repro Med Systems, Inc. dba KORU Medical Systems (NASDAQ: KRMD) ("KORU Medical" or the "Company"), a leading medical technology company focused on the development of innovative and easy-to-use home infusion solutions, today announced that the Company will report first quarter 2022 financial results on Wednesday, May 4, 2022. KORU Medical’s management will host a conference call and webcast at 4:30 p.m. ET that day to discuss the financial results and provide a corp